

## Single-dose Intravenous Dexmedetomidine as an Adjuvant for Prolongation of Spinal Anesthesia

Divya N Kheskani<sup>1</sup>, Heena S Chhanwal<sup>2</sup>, Meshwa S Desai<sup>3</sup>, Avni H Thacker<sup>4</sup>

<sup>1</sup>Assistant Professor, <sup>2</sup>Professor, <sup>3</sup>Resident, Department of Anaesthesia, GCS Medical College Hospital and Research Centre, Chamunda Bridge, Ahmedabad, Gujarat 380025, India.

### Abstract

**Context:** Dexmedetomidine is  $\alpha_2$  agonist used as adjuvant to spinal anesthesia for prolongation of sensory, motor block, postoperative analgesia. **Aims:** To study the effect of single-dose IV dexmedetomidine on hemodynamic profile, sensory-motor block prolongation, sedation. **Methods and Material:** 100 adult patients of ASA 1 and 2 posted for elective infraumbilical surgery were included. They were randomly divided into 2 groups. Group D received intravenous dexmedetomidine 0.5  $\mu\text{g}/\text{kg}$  over 10 min slowly. Group M - 0.5 mg/kg over 10 mins. Both drugs were administered 15 min after spinal anaesthesia with 15 mg 0.5% intrathecal bupivacaine heavy. Vital data, duration of sensory and motor block, sensory regression, Ramsay Sedation score and side effects were evaluated. **Results:** Duration of sensory block in Group D was  $308 \pm 20$  min prolonged than Group M  $200 \pm 15$  min. Duration of two segment regression time in Group D -  $140 \pm 8$  min more than Group M  $120 \pm 6$  min. Ramsay sedation score was slightly more for Group D without any respiratory depression. Patients of both groups remained hemodynamically stable through out with minimal side-effects. **Conclusions:** Intravenous dexmedetomidine significantly augments the sensory and motor block of intrathecal bupivacaine providing excellent sedation.

**Keywords:** Dexmedetomidine; Midazolam; Motor and sensory block; Sensory regression, Sedation.

### How to cite this article:

Divya N Kheskani, Heena S Chhanwal, Meshwa S Desai, et al. Single-dose Intravenous Dexmedetomidine as an Adjuvant for Prolongation of Spinal Anesthesia. Indian J Anesth Analg. 2020;7(2):493–499.

### Introduction

Spinal anesthesia is unique form of regional anesthesia where many drugs as adjuvant agents can be added to supplement and prolong sensory and motor blockade in large no of patients with less amount of drugs undergoing lower abdominal surgeries, sedation plays an important role as it provides anxiolysis and amnesia.<sup>1-4</sup>

In modern era anesthetists are fortunate to have agents that can be used intrathecally or intravenously

to augment the duration and efficacy of block and we call them adjuvants. Epinephrine, magnesium sulphate, fentanyl, midazolam, clonidine were used until now and now-a-days dexmedetomidine is trending.

Dexmedetomidine is a selective alpha-2 agonist, newer congener of clonidine and is 8 times more selective. It was first introduced for short-time intensive care unit sedation in 1999. Since, then it is rapidly emerging drug now-a-days as an adjuvant to regional anesthesia, general anesthesia,

**Corresponding Author:** Heena S Chhanwal, Professor, Department of Anaesthesia, GCS Medical College Hospital and Research Centre, Chamunda Bridge, Ahmedabad, Gujarat 380025, India.

**E-mail:** drmrshc@gmail.com

**Received on** 07.12.2019, **Accepted on** 28.01.2020

MAC, premedication, postoperative sedation and analgesia. it induces cooperative sleep, does not disturb the sleep architecture or respiratory drive, thus proves as an excellent drug for sedation in intubated/nonintubated patients in critical care and icu short procedures.<sup>5</sup> Alpha-2 agonists are being increasingly used as adjuvants as they provide sedation, analgesia, hypnosis and sympatholysis without respiratory depression. Midazolam is among the currently available benzodiazapine with fast onset, short recovery time, hence widely used sedative in spinal anesthesia and produces good sedation to counter act anxiety of patients.<sup>6</sup>

We conducted this randomized, prospective, double blinded clinical study to study the effect of single dose dexmedetomidine by administering it intravenously in association with spinal anesthesia and compared with midazolam

## Materials and Methods

We carried out prospective, double blind randomized study after approval of ethical committee. Written and informed consent was obtained from all the participating patients. We studied 100 adult patients of physical status American Society of Anesthesiologists ASA 1 and 2, of either sex aging from 25 to 60 years posted for elective infraumbilical surgeries and randomly allocated into two groups. Patients excluded were, those refusing of giving consent, bleeding diathesis, infection at the puncture site, belonging to ASA 3 and 4 Patients on  $\alpha_2$  adrenergic receptors antagonists, calcium channel blockers, or angiotensin-converting enzyme inhibitors, Patients having cardiac rhythm abnormalities, Any drug allergy, pregnancy, lactating mother, obesity, Any major illness involving RS, CVS or CNS. All contraindication to spinal analgesia including, spinal deformity, patient on anticoagulants, preexisting neurological deficits in lower extremities were excluded. Preanesthesia examination was done preoperatively with a detailed history, general and systemic examinations, airway and back and spine were also examined. All routine laboratory investigations were done. Patients received 0.5 mg alprazolam tablet night prior to surgery and were kept nil by mouth on day of surgery. In the preoperative recovery room, peripheral IV line was secured with 18 g cannula and they were preloaded with 10 ml/kg of ringer lactate solution. Patients were then randomly allocated into either of two groups:

*Group D:* Intrathecal 0.5% bupivacaine heavy

3 ml, followed by infusion of intravenous dexmedetomidine 0.5 mcg/kg over 10 min.

*Group M:* Intrathecal 0.5% bupivacaine heavy 3 ml followed by infusion of midazolam 0.05 mg/kg over 10 mins.

Above study drugs were administered, 15 min after spinal anesthesia with bupivacaine 0.5% 15 mg ( $n = 50$  per group).

## Preparation of Infusion

One ml of injection dexmedetomidine, will be diluted in 19 ml of normal saline; hence, the concentration of the drug in the solution is 5  $\mu$ g/ml. Similarly for Group M: The infusion will be prepared by diluting 3 ml midazolam in 17 ml normal saline. Total infusion volume for each group is 20 ml.

These infusions were prepared by an independent senior resident who was not involved in the subsequent phases of the study. Thus, both the resident conducting the case as well as the patient were unaware of the assigned group in all the cases.

Standard monitoring was done, which includes noninvasive Blood Pressure (BP), electrocardiography, Heart Rate (HR), and Oxygen ( $O_2$ ) saturation. All patients were supplemented with 4 L/min of  $O_2$  by simple face (NRBM) mask. Subarachnoid block with 3 ml of 0.5% bupivacaine was performed in the L3-L4 interspace using a 25-gauge Quincke's spinal needle with the patient in sitting position.

After performing the spinal block vital signs were recorded at 0, 5, 10, 15 min initially, and every 30 min thereafter, 15 minutes after the subarachnoid block, dexmedetomidine group (Group D) received dexmedetomidine infusion 0.5  $\mu$ g/kg over 10 min, and group (Group M) received midazolam 0.05 mg/kg (not more than 2.5 mg) infusion over 10 min.

## Observations

Following variables were assessed:

Onset, height, duration, and regression of sensory block (two segment regression) by the loss of pinprick sensations. Before giving the study drug or placebo, the sensory level was recorded after giving the study drug Sensory block assessed every 2 min for the first 10 min and thereafter, every 5 min during surgery. In the Postanesthesia Care Unit (PACU), recorded every 15 min for the next 4 h or regression to S1 level, after which the patient

was shifted to the ward. The time of giving the intrathecal injection was considered as zero. Motor block was assessed by modified bromage scale:

- 0 No paralysis, able to flex hips/knees/ankles;
- 1 Able to move knees, unable to raise extended legs;
- 2 Able to flex knees, unable to flex knees;
- 3 Unable to move any part of the lower limb;

The level of sedation was evaluated using six point Ramsay Sedation Scale (RSS):

- 1. Patient fully awake and oriented;
- 2. Patient cooperative, drowsy and tranquil;
- 3. Patient asleep but responds to oral commands;
- 4. Asleep, but responds to light glabellar tap;
- 5. Asleep, sluggish response to light glabellar tap;
- 6. Asleep, no response.

Postoperative pain was assessed using Visual Analog Scale (VAS), every 15 min until the first

analgesic given, and 4 hourly for the next 24 h, rescue analgesia will be given in the form of injection diclofenac sodium 75 mg Intramuscular (IM) when VAS score was more than 3.

For the purpose of this study, hypotension was considered Systolic BP of < 90 mm Hg and treated by foot end elevation, and fluid bolus of 300 to 500 ml. If such hypotension did not respond to this fluid administration, then injection mephentermine 5 mg IV was administered. If it did not respond to two repeated doses of mephentermine, then dopamine infusion was started to maintain the BP. Bradycardia for these cases was defined as HR < 50 beats/min (20% decrease from the baseline), and if persist treated with 0.6 mg of intravenous atropine.

**Results**

There was no statistically significant difference in all subjects in Group D and Group C with respect to demographic profile that included patients age, sex, height, weight, ASA physical status and duration of surgery, (Table 1).

**Table 1:** Demographic Data

	Group D	Group M	p - Value
Age (years)	43 ± 9.4	42 ± 8.5	0.578
Height (cm)	145 ± 5	147 ± 5.2	0.0528
Weight (kg)	55 ± 5.4	53 ± 6.1	0.085
Duration of Surgery (min)	130 ± 15.4	133 ± 22	0.435
ASA Grade (1:2)	35:15	40:10	NS

The two segment regression time in Group D was 148 ± 8 min and Group M was 120 ± 6 min. with p - value being (< 0.0001) statistically highly significant, (Table 2). The duration of motor block was 230 ± 15 min in Group D and 160 ± 10 min in Group M with p

- value being < 0.0001 statistically highly significant, (Table 2). Total duration of sensory block for Group D was prolonged (308 ± 20 min) than Group M (200 ± 15 min) with p - value < 0.0001 and difference is statistically highly significant, (Table 2).

**Table 2:** Spinal anesthesia parameters

	Group D	Group M	p - value
Duration of 2 Segment Regression (min)	148 ± 8	120 ± 6	< 0.0001
Duration of Motor block (min)	230 ± 15	160 ± 10	< 0.0001
Duration of Sensory block (Request for 1 <sup>ST</sup> rescue analgesia) (min)	308 ± 20	200 ± 15	< 0.0001

Sedation score was measured using modified Ramsay Sedation Score and was quite similar intraoperatively through out in both groups with

dexmedetomidine having slightly higher scores and good sedation without any respiratory depression than Group M, (Table 3).

**Table 3:** Modified Ramsay sedation score (The time of giving the drug is taken as 0)


Time	Group D	Group M
0	2	2
15	3.64 ± 0.6	3.6 ± 0.3
30	4.3 ± 0.7	3.9 ± 0.7
45	4.6 ± 0.5	4.2 ± 0.5
60	4.6 ± 0.4	4.2 ± 0.4
75	4.56 ± 0.5	4.4 ± 0.2
90	4.4 ± 0.5	4.3 ± 0.2
120	4.2 ± 0.6	4.0 ± 0.4
180	3.2 ± 0.5	3.2 ± 0.2

Six (12%) patients of Group M had postoperative shivering which was managed, no patient in Group D had shivering (*p* - value 0.0112, not significant). While nausea occurred in 9 (18%) patients in Group D and 2 (4%) patients in Group M, *p* - value 0.1398.


However, only 1 (2%) patient in Group D had vomiting (*p* - value 0.3197), (Table 4). Patients in both Groups D and M remained hemodynamically stable through out the surgery, (Figs. 1 and 2).

**Table 4:** Side-effects

	Group D	Group M	<i>p</i> - value
Shivering	0	6 (12%)	0.0112
Nausea	9 (18%)	4 (8%)	0.1398
Vomitting	1 (2%)	0	0.3197



**Fig. 1:** Group D vitals (pulse, systolic blood pressure, diastolic blood pressure).



**Fig. 2:** Group M vitals (pulse, systolic blood pressure, diastolic blood pressure).

## Discussion

Subarachnoid block causes sympatholysis which is hallmark feature of central neuraxial blockade. The hemodynamic stability was attained after 15 mins of giving intrathecal bupivacaine, after which we administered intravenous dexmedetomidine and midazolam slowly over 10 mins.

Jyotsna Kubre et al. in her study entitled "Single dose IV dexmedetomidine prolongs spinal anesthesia with hyperbaric bupivacaine" administered intravenous dexmedetomidine 45 mins after the intrathecal bupivacaine.<sup>7</sup>

In our study, patients of both groups Group D and Group M remained vitally stable throughout the surgery. The decrease in heart rate was more evident in Group D as compared to Group M and was not statistically significant. This is due to the postsynaptic activation of  $\alpha_2$  adenoreceptors in CNS, that results in decrease in sympathetic activity and circulatory levels of catecholamines.<sup>8,9</sup> Similar observation was made by Jyotsna et al. and Group D had decrease in heart rate in her study.<sup>7</sup>

Aantaa R, Jaakola ML in their study "A comparison of dexmedetomidine an alpha-2 adenoreceptor agonist and midazolam as a premedication intramuscularly for minor gynecological surgeries" and observed that bradycardia was caused by dexmedetomidine but it was longlasting when given as premedication.<sup>10</sup>

In other studies, continuous infusion was administered throughout the procedure, hypotension and bradycardia remained intraoperatively as well as postoperatively which lead to increase consumption of other drugs to treat these effects.<sup>11-13</sup>

Henceforth, when peak hemodynamic effects of intrathecal subarachnoid block were settled, in our study, single-dose intravenous dexmedetomidine was given slowly to overcome these complications. In both groups of our study there was decrease in BP which was clinically and statistically not significant, normally dexmedetomidine does not have any direct effect on heart rate. Although it causes a dose dependent increase in coronary vascular resistance and  $O_2$  extraction but the demand/supply ratio is unaltered. It shows biphasic response occurs after administration of bolus 1 microgram/kg causing transient rise in BP and reflex decrease in heart rate. This initial response is due to effect of B adenoreceptor stimulation of vascular smooth muscle<sup>14</sup> in our study as we administered the drug

slowly over 10 mins there was stabilization of Heart Rate and BP 10-15% below the baseline value.

This result was very-well supported by Mamta Mahobia et al. as they had similar timing and conclusion.<sup>7</sup> However, Tekin M, in his research "effect of dexmedetomidine IV on duration of spinal anesthesia with prilocine" found no significant difference in MAP in dexmedetomidine group.<sup>11</sup>

In our research, the duration of 2 segment regression in Group D pt. was  $148 \pm 8$  min and Group M was  $120 \pm 6$  min,  $p$  - value  $< 0.0001$  being statistically highly significant. The total duration of sensory block was prolonged in Group D  $308 \pm 20$  min than Group M  $200 \pm 18$  min. The total duration of motor block in Group D was  $230 \pm 15$  mins and group M  $160 \pm 10$  mins. These prolonged effects in patients of Group D can be explained by the fact that the site of action of dexmedetomidine is locus ceruleus and is mediated by hyperpolarization of nonadrenergic neurons and inhibits noradrenaline release and thus inhibits activity of descending medullospinal noradrenergic pathways.<sup>15</sup>

Jyotsna et al., study also concluded that the duration of sensory blockade was prolonged in dexmedetomidine group  $341.7 \pm 20.8$  min as compared to control group  $329 \pm 22.1$ . The 2 dermatomal regression time was also prolonged  $115.5 \pm 8.8$  as compared to control group  $95.8 \pm 14$  min. The motor block was also augmented in Group D  $278 \pm 11$  min as compared to control group -  $250 \pm 14.8$  min.<sup>7</sup>

Bajwa S et al. who reviewed "Dexmedetomidine: An adjuvant making large roads into clinical practice," had similar observations that dexmedetomidine as an adjuvant in neuraxial anesthesia prolongs the sensory and motor blockade with more intense and good postoperative analgesia.<sup>15,16</sup>

Honge et al.<sup>13</sup> who administered intravenous dexmedetomidine as an adjuvant to regional anesthesia with hyperbaric bupivacaine observed that complete resolution of motor and sensory blockade was significantly prolonged in Dexmedetomidine group and the findings of our present study corroborate the result.

We assessed sedation by modified Ramsay sedation score which was quite similar intraoperatively throughout in both groups, Group D has slightly higher scores and good sedation without any respiratory depression than Group M. Evidence suggests that of the 3 major receptor subtypes  $\alpha_2A$ ,  $\alpha_2B$  and  $\alpha_2C$  in CNS,  $\alpha_2A$  and  $\alpha_2C$  predominate in CNS and are responsible for

sedative, analgesic and sympatholytic components of agonist action.<sup>17</sup>

Dexmedetomidine induced sedation is called “Cooperative sedation” as it does not cause much respiratory depression with wide safety margins, sleep induced with it has rapid eye movement and is easily arousable.<sup>18</sup> However, the sedation induced by drugs acting on GABA system such as midazolam or propofol that produce clouding of Consciousness.<sup>7</sup> Rekha Kumar, Ani Kumar concluded that Ramsay Sedation Score was significantly higher in dexmedetomidine group as compared to control group. Mustafa et al. I noted that the median sedation score was 4 in dexmedetomidine group in their study.<sup>13</sup>

In our study, none of the patients of Group D had shivering as compared to Group M patients where 6 (12%) had postoperative shivering ( $p$  - value 0.0112). The incidence of nausea was in 9 (18%) patients in Group D and 4 (8%) patients in Group M and vomiting was observed in only 1 patient in Group D.

Venn RM et al. in their study “Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care” had similar observations.<sup>20</sup> Elvan EG et al. carried out a study to observe the incidence of postoperative shivering in patients undergoing elective abdominal hysterectomy. His study results proved that intraoperative infusion of dexmedetomidine prevented postoperative shivering.<sup>21</sup>

A study entitled “A balanced anesthesia with dexmedetomidine decreases postoperative nausea and vomiting after laproscopic surgery” was done by Massad IM et al. He concluded that on combining dexmedetomidine to other anesthetic agents for patients posted for general anesthesia, there was significant decrease in incidence of postoperative nausea and vomiting.<sup>22</sup> All these findings are similar to our study and thus strengthen our results.

## Conclusion

We concluded that dexmedetomidine is superior to midazolam as it provides arousable sedation, analgesia, hypnosis and sympatholysis without causing respiratory depression. Single-dose IV dexmedetomidine 0.5 microgram/kg given slowly prolongs the durations of sensory and motor blockade.

Midazolam is a nearly ideal supplement providing sedation with effective anxiolysis, fast onset, short recovery time, predictable depth

of anesthesia, with minimal side-effects and no evidence of accumulation.

**Acknowledgment:** Nil.

**Conflict of Interest:** Nil.

## References

1. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. *Anesthesiology* 2000;93:1345-359.
2. Saxena H, Singh S, Ghildiyal S. Low-dose intrathecal clonidine with bupivacaine improves onset and duration of block with hemodynamic stability. *Internet J Anesthesiol* 2009;23:1.
3. Thakur A, Bhardwaj M, Kaur K, et al. Intrathecal clonidine as an adjuvant to hyperbaric bupivacaine in patients undergoing inguinal herniorrhaphy: A randomized double-blinded study. *J Anesthesiol Clin Pharmacol* 2013;29:66-70.
4. Sethi BS, Samuel M, Sreevastava D. Efficacy of analgesic effects of low-dose intrathecal clonidine as adjuvant to bupivacaine. *Indian J Anesth.* 2007;51:415-19.
5. Eren G, Cukurova Z, Demir G, et al. Comparison of dexmedetomidine and three different doses of midazolam in preoperative sedation. *J Anesthesiol Clin Pharmacol* 2011;27:367-72.
6. Midazolam in Spinal Anesthesia—Intrathecal or Intravenous? By Beyazit Zencirci Submitted: September 13<sup>th</sup> 2013 (Reviewed: June 12<sup>th</sup> 2014 Published: September 3<sup>rd</sup> 2014); DOI: 10.5772/58750.
7. Kubre Jyotsna, Sethi Ashish. Single-dose intravenous dexmedetomidine prolongs spinal anesthesia with hyperbaric bupivacaine, *Anesth Essays Res* 2016 May-Aug;10(2):273-77. doi: 10.4103/0259-1162.174465 PMID: PMC4864683 PMID: 27212760
8. Yazbek-Karam VG, Aouad MM. Perioperative uses of dexmedetomidine. *Middle East J Anaesthesiol.* 2006;18:1043-58. [PubMed] [Google Scholar]
9. Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. *Anesth Analg.* 2002;95:461-6. [PubMed] [Google Scholar]
10. Aantaa R, Jaakola ML, Kallio A, et al. A comparison of dexmedetomidine, and alpha 2-adrenoceptor agonist, and midazolam as IM premedication for minor gynecological surgery. *Br J Anesth* 1991;67:402-09.
11. Tekin M, Kati I, Tomak Y, et al. Effect of dexmedetomidine IV on the duration of spinal anesthesia with prilocaine: A double-blind, prospective study in adult surgical patients. *Curr Ther Res* 2007;68:313-24.

12. Hong JY, Kim WO, Yoon Y, et al. Effects of intravenous dexmedetomidine on low-dose bupivacaine spinal anesthesia in elderly patients. *Acta Anesthesiol Scand* 2012;56:382-87.
  13. Al-Mustafa MM, Badran IZ, Abu-Ali HM, et al. Intravenous dexmedetomidine prolongs bupivacaine spinal analgesia. *Middle East J Anesthesiol* 2009;20:225-31.
  14. Patel CR, Engineer SR, Shah BJ, et al. Effect of intravenous infusion of dexmedetomidine on perioperative hemodynamic changes and postoperative recovery: A study with entropy analysis. *Indian J Anesth* 2012;56:542-46.
  15. Bajwa S, Kulshrestha A. Dexmedetomidine: An adjuvant making large inroads into clinical practice. *Ann Med Health Sci Res* 2013;3:475-83.
  16. Mannion S. Sedation, spinal anesthesia and older patients. *J Postgrad Med* 2007;53:155.
  17. Nelson LE, Lu J, Guo T, et al. The alpha 2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. *Anesthesiology* 2003 Feb;98(2):428-36.
  18. Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. *Crit Care* 2000;4:302-308.
  19. Kumari Rekha, Kumar Anil. Intravenous dexmedetomidine as an adjunct to subarachnoid block: A simple effective method of better perioperative efficacy. *J Anesthesiol Clin Pharmacol* 2017 Apr-Jun;33(2):203-208. doi: 10.4103/joacp.JOACP\_367\_15 PMID: PMC5520593.PMID: 28781446
  20. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. *Br J Anesth* 2002;88:669-75.
  21. Elvan EG, Oç B, Uzun S, et al. Dexmedetomidine and postoperative shivering in patients undergoing elective abdominal hysterectomy. *Eur J Anesthesiol* 2008;25:357-64.
  22. Massad IM, Mohsen WA, Basha AS, et al. A balanced anesthesia with dexmedetomidine decreases postoperative nausea and vomiting after laparoscopic surgery. *Saudi Med J* 2009;30:153741.
- 
-